Latest Conference Articles

MSK experts discuss FLAURA2 updates, emerging targets in mesothelioma, and next-gen immunotherapies from the 2026 European Lung Cancer Congress.

Tisotumab vedotin plus carboplatin and pembrolizumab ± bevacizumab elicited antitumor acitivity in a phase 1/2 cervical cancer trial.

HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety profiles per 2026 SGO data.

Roisin E. O'Cearbhaill reviews a phase 1/2 trial evaluating REGN5668, a MUC16×CD28 bispecific antibody, in combination with other targeted therapies for recurrent ovarian and endometrial cancers.

Mirvetuximab soravtansine plus carboplatin showed promise in patients with FRα-positive platinum-sensitive ovarian cancer.

The novel FRα-targeted ADC sofetabart mipitecan showed strong antitumor activity in patients with heavily pretreated platinum-resistant ovarian cancer.

Trastuzumab pamirtecan, a novel antibody-drug conjugate, showed initial efficacy signals in pretreated patients with HER2-expressing endometrial cancer.

Final ROSELLA overall survival results show adding relacorilant to nab-paclitaxel reduces risk of death by 35% in platinum-resistant ovarian cancer.

Experts from Memorial Sloan Kettering Cancer Center discuss updates from the 2026 European Lung Cancer Congress.

Findings from the PARADIGM trial suggest that the use of azacitidine and venetoclax could replace intensive chemotherapy in younger, fit patients with acute myeloid leukemia.

Dr Nicolas Girard discusses PALOMA-2 at ELCC 2026, highlighting the 85% ORR and safety of subcutaneous amivantamab plus lazertinib in first-line EGFR+ NSCLC.

With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses practice-changing presentations from the 2026 ASCO GU Cancers Symposium.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

The ASTEROID trial shows adding durvalumab to SBRT significantly cuts tumor progression in early-stage NSCLC, though OS and DFS benefits remain uncertain.

Phase 2 interim safety data presented at the EBMT 2026 Annual Meeting suggest no additive toxicity with the novel combination chronic GVHD regimen.

New first-line ES-SCLC data show iza-bren plus serplulimab drives 88% responses and manageable safety, setting up phase 3 trials.

Phase 1 data show that setidegrasib degrades KRAS G12D, delivering durable NSCLC responses with manageable safety and biomarker-linked benefit as phase 3 plans advance.

ABC trial interim results demonstrate effective, short-duration prophylaxis without conventional immunosuppressants and with dose-reduced cyclophosphamide.

Most patients with heavily pretreated chronic GVHD experienced clinical benefit with axatilimab, with the majority continuing treatment after approval.

ELCC 2026 spotlights lung cancer breakthroughs—ADCs, EGFR combo sequencing, HER2 TKIs and SCLC bispecifics—reshaping treatment choices.

Phase 3 results show that fecal microbiotherapy achieved a 62% GI response rate and a 54% 1-year survival in patients who had failed both corticosteroids and ruxolitinib.

In patients with high-grade uterine sarcoma who achieved disease control, cabozantinib did not prolong survival and had added toxicity.

Ozekibart, irinotecan, and temozolomide yielded a high response rate and maintained tolerability in patients with relapsed/refractory Ewing sarcoma.

Data presented at ESMO Targeted Anticancer Therapies Congress 2026 support ongoing phase 3 evaluation.

David R. Wise, MD, PhD, discusses the use of gotistobart, a next-generation CTLA-4 targeting antibody, in prostate cancer.

Sacituzumab govitecan plus pembrolizumab may enable bladder preservation in MIBC.

AI plus digital pathology and clinical data pinpoint HR+/HER2- early breast cancers with unexpectedly low distant recurrence, sharpening prognosis and guiding endocrine or chemo choices.

IASLC TTLC 2026 spotlights patient voices, ctDNA MRD, EGFR co-mutations, and ADCs—plus real-world gaps in testing and multidisciplinary lung care.

Tumor board insights reveal how ctDNA-guided ESR1 testing and SERENA-6 strategies may reshape HR+ metastatic breast cancer and local therapy choices.

How GLP-1 weight-loss drugs fit after breast cancer: emerging survival hints, new ESMO cautions during chemo, and smart tapering to avoid rebound.